Alpha-Lipoic Acid: Why "600 mg" Is Really 300 mg of Active R

Alpha-Lipoic Acid Benefits: Graded by Evidence

Looking for a tested product? See our best alpha-lipoic acid ranked by cost per 100mg of active R →

Tier 1: diabetic peripheral neuropathy — the best-evidenced benefit, but route changes the answer

This is where ALA's data is strongest, and also where the fine print matters most. A meta-analysis pooling four randomized, placebo-controlled trials — ALADIN, ALADIN III, SYDNEY, and NATHAN II, totaling 1,258 patients — found that 600 mg/day of ALA given intravenously for three weeks improved total neuropathy symptom scores by 24.1% versus placebo, with 52.7% of treated patients seeing at least a 50% improvement versus 36.9% on placebo (Ziegler 2004, PMID: 14984445). That's a real, meaningful effect — but it's a hospital IV drip, not the oral capsule sold as a supplement.

Oral ALA also has supportive evidence: a 2023 meta-analysis of 10 randomized trials (1,242 patients) using 600, 1,200, or 1,800 mg/day found a dose-related improvement in symptom scores and patient-reported satisfaction (Hsieh 2023, PMID: 37630823). But a 2024 Cochrane review that specifically restricted its analysis to trials lasting six months or longer — almost all oral — concluded ALA "probably has little or no effect on neuropathy symptoms or adverse events at six months," with a confidence interval that didn't reach the threshold for a clinically meaningful difference (Baicus 2024, PMID: 38205823). Put together: the IV result is real, the short-term oral result is favorable but weaker, and the long-term oral result is disappointing. If you're buying an oral supplement expecting the 24% IV figure, you're likely to be let down. See our full does-it-work breakdown for the complete route-by-route evidence table.

Tier 2: glycemic markers and weight — real, but modest and inconsistent

For blood sugar, the picture is split. A meta-analysis of 24 randomized trials across people with various metabolic diseases found ALA significantly reduced fasting glucose (standardized mean difference −0.54) and HbA1c (−1.22) (Akbari 2018, PMID: 29990473). But a separate meta-analysis of 10 studies (553 patients) restricted to people with uncomplicated type 2 diabetes found no significant effect on either fasting glucose or HbA1c (Ebada 2019, PMID: 32184879). The likely explanation is that the positive result is driven by broader, sicker metabolic-disease populations with more room to improve — not a general glucose-lowering effect you should expect if your diabetes is otherwise well controlled. It is not a substitute for diabetes medication.

For weight, a meta-analysis of 12 trials found ALA supplementation reduced body weight by 0.69 kg and BMI by 0.38, with no significant change in waist circumference (Namazi 2018, PMID: 28629898). That's roughly a pound and a half — a statistically real effect, but not a weight-loss result by any practical measure.

The buying signals: R-ALA vs racemic, and taking it on an empty stomach

Two practical questions come up constantly when shopping for ALA, and both have a dedicated page with the full breakdown — here's the headline version. First, only the R-(+) enantiomer is the form your body actually makes and uses; most commercial ALA is racemic, a 50/50 mix of R and the largely inactive S form, so a labeled "600 mg" delivers about 300 mg of active R (Salehi 2019, PMID: 31405030). A stabilized sodium-R-lipoate form reaches higher peak and total blood levels than plain racemic ALA in a small human pharmacokinetic study (n=12) (Carlson 2007, PMID: 18069903) — but priced per milligram of actual active R, bulk racemic is still the cheaper source; see R vs racemic for the full cost comparison.

Second, ALA is usually taken on an empty stomach, about 30 minutes before a meal. That advice traces back to a small human pharmacokinetic study that found taking it with food measurably lowered both peak and total blood levels compared to taking it fasted (Gleiter 1996, PMID: 8858282). It's a short, older study rather than a large modern trial, but it's the basis for the timing convention used across most ALA products and the oral trials above. See our dosage guide for the full 600 mg/day protocol.

Safety notes that affect who should chase these benefits

Two cautions are worth knowing before you buy ALA for any of the benefits above, beyond the general hypoglycemia risk with insulin or sulfonylureas covered on our does-it-work page.

Other marketed claims: antioxidant, skin, and cognitive support

ALA is often sold as a general antioxidant, a skin or "anti-aging" ingredient, and occasionally for cognitive support. The biological rationale — ALA is a genuine mitochondrial cofactor and has antioxidant activity in cell and animal models — is real, but we did not find a meta-analysis quantifying a human effect size for skin appearance or cognition the way there is for neuropathy, glucose, or weight. Treat those claims as plausible extrapolation from mechanism, not as benefits with trial-backed numbers behind them, and don't expect them to be graded here alongside the tiers above.

Alpha-lipoic acid benefits at a glance

Does Alpha-Lipoic Acid Work? The Honest Evidence (IV > Oral)

The mechanism, and why the route of delivery is on every line

Alpha-lipoic acid is an antioxidant and a mitochondrial cofactor, and only the R-(+) enantiomer is the body-made, active form (Salehi 2019); trials used racemic ALA at the standard 600 mg/day. The single most important honest caveat isn't the dose — it's intravenous vs oral. The headline neuropathy result was achieved with an IV drip in a hospital, and oral capsules are absorbed less reliably. So the table below flags the route for every result, because the strong IV finding does not automatically transfer to the oral capsule you buy off a shelf — conflating them is the most common way ALA's evidence gets oversold.

What the trials show — by outcome and route

Read together: the ALA case is modest and route-dependent — a strong intravenous neuropathy result that the oral capsule only partly reproduces (and Cochrane finds little durable oral effect), a split glycemic signal that's positive in broad metabolic disease but null in uncomplicated T2D, and a small weight effect. It's a reasonable adjunct for diabetic nerve symptoms, not a glucose or weight-loss drug. (A separate dose-response meta-analysis, Vajdi 2020, estimated a larger weight drop of ~−2.29 kg but no significant waist change — still a modest effect.)

Safety landmines worth respecting

ALA is generally well tolerated (mild GI, occasional rash), but two cautions are genuine "monitor and discuss with your clinician" issues:

Who it's most reasonable for

• People with diabetic nerve symptoms wanting an adjunct — understanding the strong evidence is intravenous, and the oral capsule's durable effect is modest at best (Baicus 2024).
• Not a substitute for diabetes medication, and not a reliable glucose-lowering or weight-loss drug.
• Get medical advice first if you take insulin or a sulfonylurea (additive hypoglycemia), have a thyroid or autoimmune history or East Asian ancestry (insulin autoimmune syndrome risk), or are pregnant or breastfeeding.

Alpha-Lipoic Acid Side Effects: GI Upset, Hypoglycemia & IAS

Looking for a tested product? See our best alpha-lipoic acid ranked by cost per 100mg of active R, which also links back to this safety detail →

Day-to-day tolerability: mild GI upset, and a smell that surprises people

Across the oral trials behind ALA's diabetic-neuropathy evidence, the compound has a consistent reputation: well tolerated. The DEKAN trial, an 800 mg/day oral dose for four months, reported no difference between ALA and placebo in the rates of adverse events (Ziegler 1997, PMID: 9051389). The 2024 Cochrane review pooling three long-term trials (1,090 participants) found little or no difference between ALA and placebo in adverse events leading to treatment discontinuation within six months (Baicus 2024, PMID: 38205823). None of that means side effects are zero — the complaints that do come up are mostly mild nausea, stomach discomfort, or heartburn, more likely early in use or with a larger single dose rather than a split one.

A second, more distinctive complaint isn't captured well in trial adverse-event tables at all: a sulfurous, faintly rotten-egg smell to burps, which some people notice within the first days of use. It follows directly from ALA's chemical structure — a five-membered ring built around a pair of sulfur atoms — and it's harmless, just unexpected if nobody warns you about it. If GI upset does bother you, taking ALA with food reduces it, though that comes at a real cost to absorption; see our dosage guide for the usual empty-stomach timing and the trade-off.

The safety issue that actually matters: hypoglycemia with diabetes medication

This is a mechanism-based caution rather than a dedicated interaction trial, but it's a real one: if you take insulin or a sulfonylurea, monitor your blood sugar more closely when starting ALA and coordinate any dose changes with your doctor rather than adjusting on your own.

Insulin autoimmune syndrome (Hirata disease): rare, but worth knowing by name

This is the side effect that gets the most attention relative to how often it actually happens, so it's worth being precise. Insulin autoimmune syndrome (IAS), also called Hirata disease, is a condition where the body produces antibodies against its own insulin, causing spontaneous hypoglycemia with unusually high measured insulin levels. It was first linked to ALA in Japan — an early case report described the association in a Japanese patient (Ishida 2007, PMID: 17586737) — and a strong genetic predisposition underlies it: the HLA-DRB1*04:06 variant in Japanese patients, and a related but distinct variant, HLA-DRB1*04:03, in the small number of European cases reported since. One Italian case series described six Caucasian patients who developed IAS after taking 600 mg/day of ALA, five carrying HLA-DRB1*04:03 and one carrying HLA-DRB1*04:06 (Gullo 2014, PMID: 24111525); a second report described two more European cases, both HLA-DRB1*04:03 (Moffa 2019, PMID: 30086435).

Those are case reports, not a population-level risk estimate — eight documented European cases is not the same as "this happens to European ALA users." For the actual population picture, Europe's food safety authority reviewed the published evidence, including 49 case reports of ALA-associated IAS in total, and found that symptoms resolved within weeks to months once ALA was stopped in every case reviewed. Separately, it cites an estimate that the overall incidence of IAS in Japan (from any cause, not ALA specifically) was about 0.017 cases per 100,000 people in 2017–2018, and states that Europe's incidence is likely even lower — while also concluding that the specific risk attributable to ALA "cannot be quantified precisely" from the available data (EFSA Panel on Nutrition 2021, PMID: 34122657). Put plainly: this is a genuinely rare reaction with a real biological mechanism and a known genetic risk group, not a common outcome you should expect. If you develop unexplained hypoglycemia while taking ALA — shakiness, confusion, sweating, without a clear cause — stop taking it and see a clinician; the condition is treatable and typically resolves once ALA is discontinued.

Two more interactions worth knowing: biotin and thiamine

• Biotin (shared transporter, not demonstrated deficiency). Researchers identified the transporter that carries the active R-(+) form of ALA into cells — the human Na⁺/multivitamin transporter, hSMVT — which is the same transporter known to carry biotin and pantothenic acid (Zehnpfennig 2015, PMID: 25971966). That's a mechanistic finding from a cell/transporter-based study, not a clinical trial showing ALA supplementation causes biotin deficiency in people. It's a reasonable reason not to stack a high-dose biotin supplement with high-dose ALA at the exact same time, not a reason to avoid the combination altogether.
• Thiamine (correct any deficiency first). ALA and thiamine (vitamin B1) both function in the same metabolic pathway, the pyruvate dehydrogenase complex. Standard clinical guidance — most relevant for people with poor nutrition or heavy alcohol use, where thiamine deficiency is more likely — is to identify and correct thiamine deficiency before or alongside starting ALA rather than layering it on top of an unaddressed deficiency. This is a mechanism-based precaution we did not find quantified in a dedicated human trial, so treat it as sensible practice rather than a documented risk with a number attached.

Alpha-lipoic acid side effects at a glance